[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100583698":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":34,"responsibleParty":52,"collaborators":19,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":56,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":19,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":36,"whyStopped":19,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Centre Henri Becquerel","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"PRECISION ARM","EXPERIMENTAL","Patient will have four imaging exam : MRI, PET-scan, ultrasound and angio\u002FMammography",[13],"Other: Imaging assessment",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"Imaging assessment","The patient will have four imaging exam : Ultrasound, angio\u002Fmammography, MRI and PET-scan",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Florian Clatot, Md, PhD","PRINCIPAL_INVESTIGATOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},"Florian Clatot, MD, PhD","CONTACT","+33276673004","florian.clatot@chb.unicancer.fr",{"name":31,"role":27,"phone":32,"phoneExt":19,"email":33},"Doriane Richard, PhD","+33232082985","doriane.richard@chb.unicancer.fr",[35],{"facility":5,"status":36,"city":37,"state":19,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"RECRUITING","Rouen","76038","France","FR",{"type":42,"coordinates":43},"Point",[44,45],1.09932,49.44313,{"lat":45,"lon":44},[48,49,50],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},{"name":31,"role":27,"phone":32,"phoneExt":19,"email":33},{"name":51,"role":23,"phone":19,"phoneExt":19,"email":19},"Floriane Clatot, MD, PhD",{"type":53,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100583698","radiological-prediction-of-response-to-neoadjuvant-chemoimmunotherapy-for-triple-negative-breast-cancer-100583698",false,"NCT06879704","Radiological Prediction of Response to Neoadjuvant Chemoimmunotherapy for Triple-negative Breast Cancer","Quadrimodal Radiological Prediction (Ultrasound, Angiography\u002FMammography, Magnetic Rsonance Imaging, Positron Emission Tomography-computed Tomgraphy Scan) of Response to Neoadjuvant Chemoimmunotherapy for Triple-negative Breast Cancer","PRECISION","Inclusion Criteria:\n\n* Signed informed consent\n* Patient with histologically proven TNBC\n* Indication for neo-adjuvant chemo-immunotherapy treatment\n* Age between 18 and 75\n* Affiliated or beneficiary of a social protection scheme\n\nExclusion Criteria:\n\n* Pregnant or breast-feeding women\n* Contraindication to immunotherapy\n* Inflammatory breast cancer (T4d)\n* Metastatic patients\n* Allergies to iodine or gadolinium\n* Patient with an augmentation prosthesis (for angiography\u002Fmammography)\n* Claustrophobic patients\n* Renal contraindication to contrast products according to SFR-CIRTACI\n* Ferromagnetic material\n* Uncontrolled diabetes (blood glucose \\>10 mmol\u002FL)\n* Patient unable to understand the study for any reason or to comply with the constraints of the trial (language, psychological, geographical problems, etc.).\n* Patient under guardianship, curatorship or safeguard of justice","FEMALE","18 Years","75 Years",{"count":66,"type":67},115,"ESTIMATED","INTERVENTIONAL",[70],"NA","The aim of our study is to find the best imaging technique, alone or in combination, that can best predict a complete response (absence of tumour cells). It also seems important to identify blood markers able to predict which patients will benefit most from treatment, with a view to personalising them, or which patients will be most at risk of toxicities, particularly related to immunotherapy, with a view to personalising monitoring.",[73],"Triple Negative Breast Cancer",[73,75,76],"chemo-immunotherapy","radiological prediction","2025-12-29",{"date":79,"type":80},"2026-01-02","ACTUAL",{"date":82,"type":80},"2025-05-28",{"date":84,"type":67},"2029-11-28",{"name":5,"class":6},1]